Physician profile
Mary Babehis
NPI 1447945787
$7,650.57
in general payments reported to CMS, 2019-2025
21 companies · $3,490 in 2025
The $3,490 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,001 · 2024: $2,159 · 2025: $3,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,596 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,595.58 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,615.39 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $846.96 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $717.71 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $658.16 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $508.96 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $497.43 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $486.66 | 2025 | |
| Corium, LLC | $435.07 | 2023-2025 | Azstarys, Adlarity |
| Lundbeck LLC | $405.13 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $319.79 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $306.62 | 2023-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $208.01 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $196.21 | 2024-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $119.67 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $107.63 | 2023-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $71.92 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $50.07 | 2024-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $47.29 | 2023-2024 | Loreev Xr |
| Acadia Pharmaceuticals INC | $19.71 | 2025 | Nuplazid |
| Noven Therapeutics, LLC | $18.59 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $13.59 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Babehis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.